Education
About Us
Working with TipRanks
Follow Us
Catherine Moukheibir Insider Profile
4 Followers
Catherine Moukheibir, Director at Ironwood Pharma, holds 0.00 shares in MoonLake Immunotherapeutics (Ticker: MLTX), holds 117.94K shares in Ironwood Pharma (Ticker: IRWD).
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
+36.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Catherine Moukheibir holds in companies
Most Profitable Insider Trade
The most profitable trade made by Catherine Moukheibir
Catherine Moukheibir's Trading History
Ironwood Pharma
Jun 12, 2025
Director
Uninformative Buy
―
$129.74K
MoonLake Immunotherapeutics
Jul 07, 2025
Director
Uninformative Buy
1.15M
$0.00
List of latest transactions for each holding click on a transaction to see Catherine Moukheibir's performance on stock
You May Also Like
Catherine Moukheibir insider profile FAQ
What is the percentage of profitable transactions made by Catherine Moukheibir?
The percentage of profitable transactions made by Catherine Moukheibir is 50%.
What is the average return per transaction made by Catherine Moukheibir?
The average return per transaction made by Catherine Moukheibir is 36.60%.
What stocks does Catherine Moukheibir hold?
Catherine Moukheibir holds: IRWD, MLTX stocks.
What was Catherine Moukheibir’s latest transaction?
Catherine Moukheibir latest transaction was an Uninformative Buy of $1.15M.
What was Catherine Moukheibir's most profitable transaction?
Catherine Moukheibir’s most profitable transaction was an Informative Sell of IRWD stock on June 10, 2024. The return on the trade was 87.70%.
What is Catherine Moukheibir's role in Ironwood Pharma?
Catherine Moukheibir's role in Ironwood Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.